Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.
Identifieur interne : 002829 ( PubMed/Checkpoint ); précédent : 002828; suivant : 002830Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.
Auteurs : R M Burch [États-Unis] ; L C MahanSource :
- The Journal of clinical investigation [ 0021-9738 ] ; 1991.
Descripteurs français
- KwdFr :
- ARN messager (génétique), Animaux, Cellules cultivées, Dinoprostone (biosynthèse), Données de séquences moléculaires, Fibroblastes (), Humains, Interleukine-1 (antagonistes et inhibiteurs), Interleukine-1 (métabolisme), Liposomes (administration et posologie), Oligonucléotides antisens (pharmacologie), Relation dose-effet des médicaments, Récepteurs immunologiques (analyse), Récepteurs immunologiques (génétique), Récepteurs immunologiques (physiologie), Récepteurs à l'interleukine-1, Souris, Séquence nucléotidique.
- MESH :
- administration et posologie : Liposomes.
- analyse : Récepteurs immunologiques.
- antagonistes et inhibiteurs : Interleukine-1.
- biosynthèse : Dinoprostone.
- génétique : ARN messager, Récepteurs immunologiques.
- métabolisme : Interleukine-1.
- pharmacologie : Oligonucléotides antisens.
- physiologie : Récepteurs immunologiques.
- Animaux, Cellules cultivées, Données de séquences moléculaires, Fibroblastes, Humains, Relation dose-effet des médicaments, Récepteurs à l'interleukine-1, Souris, Séquence nucléotidique.
English descriptors
- KwdEn :
- Animals, Base Sequence, Cells, Cultured, Dinoprostone (biosynthesis), Dose-Response Relationship, Drug, Fibroblasts (drug effects), Humans, Interleukin-1 (antagonists & inhibitors), Interleukin-1 (metabolism), Liposomes (administration & dosage), Mice, Molecular Sequence Data, Oligonucleotides, Antisense (pharmacology), RNA, Messenger (genetics), Receptors, Immunologic (analysis), Receptors, Immunologic (genetics), Receptors, Immunologic (physiology), Receptors, Interleukin-1.
- MESH :
- chemical , administration & dosage : Liposomes.
- chemical , analysis : Receptors, Immunologic.
- chemical , antagonists & inhibitors : Interleukin-1.
- chemical , biosynthesis : Dinoprostone.
- drug effects : Fibroblasts.
- chemical , genetics : RNA, Messenger, Receptors, Immunologic.
- chemical , metabolism : Interleukin-1.
- chemical , pharmacology : Oligonucleotides, Antisense.
- chemical , physiology : Receptors, Immunologic.
- Animals, Base Sequence, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Mice, Molecular Sequence Data, Receptors, Interleukin-1.
Abstract
Phosphodiester and phosphorothioate oligodeoxynucleotides (18 mers) were constructed antisense to sequences of the recently cloned murine and human IL-1 receptors. Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion. Murine sense oligonucleotide and an oligonucleotide antisense to human IL-1 receptor were without effect. Moreover, murine antisense oligonucleotides did not affect tumor necrosis factor- or bradykinin-stimulated PGE2 synthesis by murine fibroblasts. Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts. The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells. When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis. In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1. These data suggest that antisense oligodeoxynucleotides may share a role in the design of antiinflammatory therapeutics.
DOI: 10.1172/JCI115421
PubMed: 1833422
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:1833422Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.</title><author><name sortKey="Burch, R M" sort="Burch, R M" uniqKey="Burch R" first="R M" last="Burch">R M Burch</name><affiliation wicri:level="2"><nlm:affiliation>Nova Pharmaceutical Corporation, Baltimore, Maryland 21224.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Nova Pharmaceutical Corporation, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Mahan, L C" sort="Mahan, L C" uniqKey="Mahan L" first="L C" last="Mahan">L C Mahan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1991">1991</date><idno type="RBID">pubmed:1833422</idno><idno type="pmid">1833422</idno><idno type="doi">10.1172/JCI115421</idno><idno type="wicri:Area/PubMed/Corpus">002980</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002980</idno><idno type="wicri:Area/PubMed/Curation">002980</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002980</idno><idno type="wicri:Area/PubMed/Checkpoint">002829</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002829</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.</title><author><name sortKey="Burch, R M" sort="Burch, R M" uniqKey="Burch R" first="R M" last="Burch">R M Burch</name><affiliation wicri:level="2"><nlm:affiliation>Nova Pharmaceutical Corporation, Baltimore, Maryland 21224.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Nova Pharmaceutical Corporation, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Mahan, L C" sort="Mahan, L C" uniqKey="Mahan L" first="L C" last="Mahan">L C Mahan</name></author></analytic><series><title level="j">The Journal of clinical investigation</title><idno type="ISSN">0021-9738</idno><imprint><date when="1991" type="published">1991</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Cells, Cultured</term><term>Dinoprostone (biosynthesis)</term><term>Dose-Response Relationship, Drug</term><term>Fibroblasts (drug effects)</term><term>Humans</term><term>Interleukin-1 (antagonists & inhibitors)</term><term>Interleukin-1 (metabolism)</term><term>Liposomes (administration & dosage)</term><term>Mice</term><term>Molecular Sequence Data</term><term>Oligonucleotides, Antisense (pharmacology)</term><term>RNA, Messenger (genetics)</term><term>Receptors, Immunologic (analysis)</term><term>Receptors, Immunologic (genetics)</term><term>Receptors, Immunologic (physiology)</term><term>Receptors, Interleukin-1</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term><term>Animaux</term><term>Cellules cultivées</term><term>Dinoprostone (biosynthèse)</term><term>Données de séquences moléculaires</term><term>Fibroblastes ()</term><term>Humains</term><term>Interleukine-1 (antagonistes et inhibiteurs)</term><term>Interleukine-1 (métabolisme)</term><term>Liposomes (administration et posologie)</term><term>Oligonucléotides antisens (pharmacologie)</term><term>Relation dose-effet des médicaments</term><term>Récepteurs immunologiques (analyse)</term><term>Récepteurs immunologiques (génétique)</term><term>Récepteurs immunologiques (physiologie)</term><term>Récepteurs à l'interleukine-1</term><term>Souris</term><term>Séquence nucléotidique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Liposomes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Dinoprostone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Liposomes</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-1</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Dinoprostone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Fibroblasts</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Messenger</term><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-1</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Interleukine-1</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligonucléotides antisens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligonucleotides, Antisense</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Cells, Cultured</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Mice</term><term>Molecular Sequence Data</term><term>Receptors, Interleukin-1</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules cultivées</term><term>Données de séquences moléculaires</term><term>Fibroblastes</term><term>Humains</term><term>Relation dose-effet des médicaments</term><term>Récepteurs à l'interleukine-1</term><term>Souris</term><term>Séquence nucléotidique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Phosphodiester and phosphorothioate oligodeoxynucleotides (18 mers) were constructed antisense to sequences of the recently cloned murine and human IL-1 receptors. Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion. Murine sense oligonucleotide and an oligonucleotide antisense to human IL-1 receptor were without effect. Moreover, murine antisense oligonucleotides did not affect tumor necrosis factor- or bradykinin-stimulated PGE2 synthesis by murine fibroblasts. Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts. The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells. When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis. In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1. These data suggest that antisense oligodeoxynucleotides may share a role in the design of antiinflammatory therapeutics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1833422</PMID><DateCompleted><Year>1991</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J. Clin. Invest.</ISOAbbreviation></Journal><ArticleTitle>Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.</ArticleTitle><Pagination><MedlinePgn>1190-6</MedlinePgn></Pagination><Abstract><AbstractText>Phosphodiester and phosphorothioate oligodeoxynucleotides (18 mers) were constructed antisense to sequences of the recently cloned murine and human IL-1 receptors. Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion. Murine sense oligonucleotide and an oligonucleotide antisense to human IL-1 receptor were without effect. Moreover, murine antisense oligonucleotides did not affect tumor necrosis factor- or bradykinin-stimulated PGE2 synthesis by murine fibroblasts. Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts. The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells. When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis. In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1. These data suggest that antisense oligodeoxynucleotides may share a role in the design of antiinflammatory therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burch</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Nova Pharmaceutical Corporation, Baltimore, Maryland 21224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1833422</ArticleId><ArticleId IdType="doi">10.1172/JCI115421</ArticleId><ArticleId IdType="pmc">PMC295584</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 1988;141:282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3063445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1989 Dec 11;17(23):10114</Citation><ArticleIdList><ArticleId IdType="pubmed">2532321</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Sep;85(17):6306-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2901097</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jul 29;241(4865):585-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2969618</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1988 Apr 25;16(8):3209-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2836790</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1988 Aug;94(4):1143-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2850056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1988 Oct;82(4):1219-24</Citation><ArticleIdList><ArticleId IdType="pubmed">2971671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1989 Jun 15;142(12):4314-20</Citation><ArticleIdList><ArticleId IdType="pubmed">2524527</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1989 Jan 30;243(2):394-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2521831</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 May;86(10):3758-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2524832</ArticleId></ArticleIdList></Reference><Reference><Citation>Agents Actions. 1989 Jun;27(3-4):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2508441</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1989 Feb;75(2):265-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2649287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1991 Mar 11;19(5):1113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1850511</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1990 Nov 14;1096(1):41-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2125233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1991 Mar 1;146(5):1617-25</Citation><ArticleIdList><ArticleId IdType="pubmed">1704400</ArticleId></ArticleIdList></Reference><Reference><Citation>Agents Actions. 1990 Aug;31(1-2):102-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2126672</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 May;86(10):3474-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2726730</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1990 Apr 12;344(6267):633-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2139180</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1990 Jan 25;343(6256):341-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2137201</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1980 Sep 1;107(1):220-39</Citation><ArticleIdList><ArticleId IdType="pubmed">6254391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 1984 Apr;82(4):367-71</Citation><ArticleIdList><ArticleId IdType="pubmed">6423734</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1975 Jul 3;394(3):483-91</Citation><ArticleIdList><ArticleId IdType="pubmed">805602</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol Immunopathol. 1988 Sep;48(3):354-61</Citation><ArticleIdList><ArticleId IdType="pubmed">2969785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1986 Nov 15;137(10):3183-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2945861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1987 May 1;138(9):2906-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2952728</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1987 Aug 31;147(1):204-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2958006</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Immunopharmacol. 1988;10(7):835-43</Citation><ArticleIdList><ArticleId IdType="pubmed">3148560</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1988 Aug 1;172(2):289-95</Citation><ArticleIdList><ArticleId IdType="pubmed">3056098</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechniques. 1988 Nov-Dec;6(10):958-76</Citation><ArticleIdList><ArticleId IdType="pubmed">2483657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1989 Oct 15;143(8):2448-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2477442</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Immunol. 1989;44:153-205</Citation><ArticleIdList><ArticleId IdType="pubmed">2466396</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Feb;85(4):1302-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2448799</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Nov;86(22):8946-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2530587</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):8034-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2530580</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):8029-33</Citation><ArticleIdList><ArticleId IdType="pubmed">2530579</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Jul;85(14):5011-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2839827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Mahan, L C" sort="Mahan, L C" uniqKey="Mahan L" first="L C" last="Mahan">L C Mahan</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Burch, R M" sort="Burch, R M" uniqKey="Burch R" first="R M" last="Burch">R M Burch</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:1833422
|texte= Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:1833422" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |